John-Paul Vermitsky

Title: John-Paul Vermitsky: Innovator in Azole Resistance Detection

Introduction

John-Paul Vermitsky is an accomplished inventor based in Philadelphia, PA (US). He has made significant contributions to the field of medical diagnostics, particularly in the detection of azole resistance in biological samples. His innovative approach has the potential to enhance the accuracy of resistance testing, which is crucial for effective treatment strategies.

Latest Patents

Vermitsky holds a patent for a method that determines azole resistance in biological samples. The patent describes a process where a biological sample is obtained, and the normalized mRNA level of the CDR1 gene is determined using qRT-PCR. The method employs a microbroth dilution assay conducted at azole concentrations of about 2-8 µg/mL to obtain a susceptible isolate. A qRT-PCR assay is then performed on this isolate to obtain an average mRNA level of CDR1. A fold-change value for CDR1 is calculated by comparing the mRNA level of the biological sample with that of the average level. A ≥2-fold change value indicates azole resistance. This method boasts a sensitivity of ≥90% and a specificity of ≥90%, making it a reliable tool for clinicians.

Career Highlights

Vermitsky is currently associated with Medical Diagnostic Laboratories, LLC, where he continues to advance his research and innovations. His work has been instrumental in developing diagnostic methods that improve patient outcomes in the medical field.

Collaborations

He collaborates with notable colleagues, including Scott E Gygax and Sean Chadwick, who contribute to the research and development efforts at Medical Diagnostic Laboratories, LLC.

Conclusion

John-Paul Vermitsky's contributions to the field of medical diagnostics, particularly in azole resistance detection, highlight his innovative spirit and dedication to improving healthcare solutions. His work exemplifies the impact of scientific research on clinical practices.